Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Ixekizumab

🥰Excellent
Catalog No. T38105Cas No. 1143503-69-8
Alias LY2439821

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM. It blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis, and psoriasis.

Ixekizumab

Ixekizumab

🥰Excellent
Purity: 95.4% (SEC-HPLC)
Catalog No. T38105Alias LY2439821Cas No. 1143503-69-8
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM. It blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis, and psoriasis.
Pack SizePriceAvailabilityQuantity
1 mg$136In Stock
5 mg$462In Stock
10 mg$678In Stock
25 mg$1,070In Stock
50 mg$1,430In Stock
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
Concentration:4.11 mg/mL
Purity:95.4% (SEC-HPLC)
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM. It blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis, and psoriasis.
In vitro
Ixekizumab (0.1-10000 pM) dose-dependently inhibits the secretion of growth-regulated oncogene (GRO)α induced by human IL-17A or human IL-17A/F heterodimers from HT-29 cells. Similarly, Ixekizumab demonstrates dose-dependent inhibition of GROα secretion from HT-29 cells induced by cynomolgus monkey IL-17A.[1]
The equilibrium KD values of Ixekizumab for IL-17A in humans and cynomolgus monkeys were 1.8 pM and 0.8 pM, respectively. Ixekizumab exhibited binding to rabbit IL-17A as well, although with a lower affinity and heterogeneous binding (with KD values of 1.3 nM and 14 nM, respectively). Notably, Ixekizumab did not demonstrate any binding to IL-17A in either mice or rats.[1]
In vivo
Ixekizumab (0.001-1 mg/kg; i.v.; C57BL/6 mice) exhibits a dose-dependent reduction in the secretion of keratinocyte chemoattractant (KC) induced by human IL-17A in the plasma of C57BL/6 mice. In male cynomolgus monkeys, intravenous (IV) administration of 1 mg/kg results in a mean elimination half-life of 6.5 days. Subcutaneous (SC) administration of 1 mg/kg yields a maximum plasma concentration of approximately 11.1 µg/mL around 72 hours post-dose, with a mean elimination half-life of about 10.3 days.[1]
AliasLY2439821
Chemical Properties
Molecular Weight146.2 kDa
Cas No.1143503-69-8
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Ixekizumab | purchase Ixekizumab | Ixekizumab cost | order Ixekizumab | Ixekizumab chemical structure | Ixekizumab in vivo | Ixekizumab in vitro | Ixekizumab molecular weight